Swirl gently or invert slowly until fully dissolved (typically 3060 seconds)
That difference shows up in outcomes: SURMOUNT-1 outperforming STEP-1 isnt about doing GLP-1 better its about activating a pathway semaglutide doesnt touch
Chen C et al
GHK-Cu published research history: - First isolated and characterized: 1973 - Continuous peer-reviewed publication: 50+ years - Published research covering: wound healing, skin biology, COPD, oxidative stress, bone, skeletal muscle, gastrointestinal, neurological, gene expression, aging - Mechanistic characterization: Multiple pathways identified, SIRT1 direct binding confirmed in 2025 - Cell and animal model validation: Extensive across multiple tissue types and species Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) research: - Commercial introduction: Early 2000s - Research base: Primarily cosmetic science and dermatology literature - Mechanistic characterization: Primarily focused on TGF-beta receptor and IL-6 pathways - Depth: Narrower tissue focus, smaller body of published mechanistic research For researchers who need a compound with extensive published mechanistic context, detailed gene expression data, or research across multiple tissue types, GHK-Cu's research depth is substantially greater
Ingredients 1 cup plant-based milk 1/4 cup chia seeds 1 scoop protein powder 1 to 2 tablespoons maple syrup 1 teaspoon vanilla extract How to Make It Add all ingredients to a blender or bowl and mix until smooth and well combined
Those frameworks remain central, particularly as the FDA repeatedly emphasizes that compounded drugs cannot be essentially a copy of an FDAapproved drug outside narrow exceptions
